Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP001260

Drug Information
SynonymsRanibizumab (genetical recombination) (JAN); Ranibizumab (USAN/INN); D05697; Lucentis; 347396-82-1; Ranibizumab (genetical recombination); Ranibizumab; Lucentis (TN)    
Trade NameLucentis    
CompanyRoche & Genentech    
IndicationAge-related macular degenerationApproved    [1]
Diabetic macular edema and retinal vein occlusionPhase III    [1]
CAS NumberCAS 347396-82-1
PubChem Substance IDSID 47207358.    
TargetVascular endothelial growth factor 1Inhibitor[2]
Vascular endothelial growth factor 1Inhibitor[2][3]
Ref 1Future pharmacological treatment options for nonexudative and exudative age-related macular degeneration. Expert Opin Emerg Drugs. 2005 Feb;10(1):119-35. To Reference
Ref 2The Effect of Intravitreal Ranibizumab on the Fellow Untreated Eye with Subfoveal Scarring due to Exudative Age-Related Macular Degeneration. Ophthalmologica. 2009 Jul 15;223(6):383-389. [Epub ahead of print] To Reference
Ref 3Roche. Product Development Pipeline. July 29 2009. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543